Skip to main content
. 2019 Nov 29;10:362. doi: 10.1186/s13287-019-1490-8

Fig. 4.

Fig. 4

fMSCs decreased oxidative damage, increased oxidative protection, improved anti-apoptosis rates, and inhibited apoptosis in the POI mouse model. a fMSCs were injected into the POI mouse model by tail intravenous. b FACS analysis of ROS expression at 2 weeks in different treatment groups. c–h ELISA analysis of MDA, SOD, CAT, LDH, GR, and GPx levels at 8 weeks in different treatment groups. i qPCR detection of SURVIVIN and BCL2 levels in different treatment groups. j qPCR analysis of CASPASE-3 and CASPASE-9 levels in different treatment groups. k Western blot analysis of SURVIVIN, BCL2, CASPASE-3, and CASPASE-9 in different treatment groups. Data are represented as the mean ± SD. ***p < 0.001 (compared with the NG group)